Skip Navigation

Annals of Oncology 2007 18(Supplement 6):vi124-vi127; doi:10.1093/annonc/mdm240
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gebbia, V
Right arrow Articles by Colucci, G
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gebbia, V
Right arrow Articles by Colucci, G
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

gastro-intestinal cancer

Second-line chemotherapy in advanced pancreatic carcinoma: a multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity and safety of the FOLFOX4 regimen in clinical practice

V Gebbia1,*, E Maiello2, F Giuliani3, N Borsellino4, M Caruso4, G Di Maggio2, F Ferraù5, R Bordonaro6, F Verderame7, P Tralongo8, L Di Cristina9, R Agueli1, P Russo1 and G Colucci3

1 Department of Experimental Oncology and Clinical Applications, University of Palermo, La Maddalena Clinic for Cancer, Palermo
2 IRCCS, Casa Sollievo della Sofferenza, San Giovanni Rotondo
3 Istituto Oncologico, Bari
4 Centro Catanese di Oncologia—Humanitas, Catania
5 Ospedale San Vincenzo, Taormina
6 Ospedale Garibaldi, Catania
7 Ospedale Civile, Sciacca
8 Ospedale De Maria, Avola
9 Ospedale di Castelvetrano, AULS 9, Trapani, Italy

* Correspondence to: Dr V. Gebbia, Department of Experimental Oncology and Clinical Applications, University of Palermo, La Maddalena Clinic for Cancer, via san Lorenzo Colli n. 312d, Palermo, Italy. Tel: +390916806710; Fax: +390916806906; E-mail vittorio.gebbia{at}tin.it

Background: In daily clinical practice second-line chemotherapy (SLCT) is frequently given to patients with advanced pancreatic cancer failing gemcitabine-based first-line chemotherapy without solid scientific support.

Patients and methods: A retrospective survey was carried out including 42 patients. Patients received standard FOLFOX4 regimen biweekly until progression or unacceptable toxicity.

Results: Six partial responses (14%) and 16 stabilizations (38%) were recorded for a tumor growth control rate of 57%. The median time to progression (TtP) was 4 months (range 1–7 months), and median overall survival (OS) was 6.7 months (range 2–9 months). A stabilization of performance status (PS) and a subjective improvement of cancer-related symptoms were recorded in 27 patients.

Conclusions: Data presented in this paper support the use of FOLFOX4 regimen in the second-line treatment of adenocarcinoma of the pancreas patients. The use of SLCT, however, should be carefully proposed to patients with good PS or those who had a good response to first-line therapy.

Key words: FOLFOX4 regimen, pancreatic carcinoma, second-line chemotherapy


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.